New clinical trial data assessing the Boston Scientific Lotus™ Valve System continue to support strong performance and safety profile

Results from clinical trials evaluating the Boston Scientific (NYSE: BSX) Lotus™ Valve System continue to show this advanced transcatheter aortic valve implantation (TAVI) therapy delivers excellent clinical outcomes with low rates of paravalvular leakage (PVL) and other complications.

One-year outcomes from REPRISE II with extended cohort and the RESPOND Post Market Registry were presented at PCR London Valves annual meeting, held this year in Berlin. 

Highlights from REPRISE II with the extended cohort (n=250) include:

  • consistent and sustained hemodynamic performance with a low all-cause mortality of 11.6%;
  • accurate positioning, with 0.0% TAV-in-TAV, ectopic placement, valve migration or embolization, and;
  • no moderate or severe PVL, as adjudicated by a core lab.

Key, 30-day outcomes in the RESPOND real-world registry (n=500) include:

  • a low all-cause mortality of 1.9%;
  • 0.0% of cases had severe PVL, 0.4% had moderate PVL and 84% had no PVL, and;
  • 0.4% rate of mal-positioning (TAV-in-TAV, ectopic placement, valve migration or embolization) in real-world complex cases.


REPRISE II is an ongoing prospective, single-arm, multi-center study designed to evaluate safety and performance of the Lotus Valve System for symptomatic patients with severe calcific aortic stenosis who are considered high risk for surgical valve replacement.


The RESPOND Registry is a prospective, open label, single arm, multi-center, observational post market study designed to assess real world performance of the Lotus Valve System. The study will collect data on clinical outcomes and device performance in 1,000 patients implanted at 50 centers around the world.  

About Boston Scientific

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.  As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.  For more information, visit and connect on Twitter and Facebook.

DISCLAIMER: Please be informed that in some EU countries (Bulgaria, Cyprus, Estonia, France, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Poland, Portugal, Romania, Slovakia, Belgium , Netherlands, Slovenia and Spain) medical device advertisement to general public is not permitted. Therefore, if you are accessing this website from one of those countries and you are not a healthcare professional, you need to exit this site immediately, since you would be viewing information that may not be legally allowed under the laws of your country of residence. Should you disregard this warning notice, Boston Scientific declines any liability as to your access to your access to such information.